It’s ironic really that I sit here writing a blog on MS and exercise in the baggiest tracksuit I could find after a month of Christmas, New Year’s and engagement celebrations.
It’s hard for us to believe, but the MS & Me blog has entered it’s seventh year in existence. As we look forward to the New Year and some interesting takes on topics, we also acknowledge to a few of our cadre of talented writers who are off to attend to other aspects of their life.
MS Index highlights severe lack of specialist healthcare services for people living with MS in Ireland
The Futureproofing Healthcare MS Index focuses on the treatment of MS across 30 European countries, with Ireland ranking in bottom third overall
It’s hard to believe that another year has gone by, and that we’re going into 2020 in a couple of weeks. I have a sneaky suspicion that I am beginning to show my age when I say things like that. The last 12 months seem to have flown by, with a lot of things going on in my home and work life, as well as in the world of MS.
A cognitive occupation-based programme for people with multiple sclerosis: A randomised controlled pilot trial to improve cognition and daily functioning for people with multiple sclerosis.
This week Joan Jordan reflects on Christmas and why she has decided to spend this festive period with her family away from home.
This week Mary Devereux reflects on her journey with MS and the things she wished she had known when diagnosed.
Everyone needs to look after their general health, both body and mind, but this can be more important when you have been diagnosed with a long-term condition like multiple sclerosis. This week Teresa McShane looks at the changes she has made to achieve a balance in body and in life.
MS Ireland welcome the decision made by the HSE to reimburse Ocrelizumab or Ocrevus for people living with relapsing MS, including those with relapsing forms of secondary progressive MS. We are disappointed that this decision has not been extended to those with primary progressive MS. Ocrelizumab, which is administered via intravenous infusion every 6 months, is the only medication currently licensed for those living with relapsing and primary progressive forms of MS.